2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
DGAP-News: Cannovum AG
/ Key word(s): Regulatory Approval
Cannovum AG (Düsseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21) is expanding its wholesale license through its subsidiary, Cannovum Health eG. The expansion includes the active ingredient license, which enables the trading of active pharmaceutical ingredients. Cannovum is now authorized to distribute dronabinol, the first cannabis-based active ingredient, to pharmacies. Active pharmaceutical ingredients are the components of a medication that are responsible for its efficacy. They trigger the essential biochemical process that ensures the medication acts in a specific way in the human body. One of the most important active ingredients of cannabis is THC, which is considered to have the greatest pharmaceutical potential and therapeutic efficacy. Cannovum's scientific sales force has undergone intensive training with medical professionals, including for the new THC active ingredients, to assist physicians and pharmacists with individual cannabis-based therapies. With the active ingredient license, Cannovum can now deal with active pharmaceutical ingredients in general and is not limited to dronabinol. In addition, Cannovum already holds the pharmaceutical wholesale licenses, including the GMP license required to map manufacturing steps in Germany. "We want to improve patient care and that's why we decided to add active substances to our portfolio. Active ingredients are the core element of every medication and indispensable in the effective therapy of patients. We want to give physicians the opportunity to find an effective individual treatment for each of their patients, because every patient deserves the best therapy," says Pia Marten, CEO of Cannovum AG.
28.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Cannovum AG |
| Rheinsberger Str. 76/77 | |
| 10115 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | ir@cannovum.com |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich |
| EQS News ID: | 1236360 |
| End of News | DGAP News Service |
|
|
1236360 28.09.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
